Correlation of prostaglandin metabolizing enzymes and serum PGE 2 levels with vitamin D receptor and serum 25(OH) 2D 3 levels in breast and ovarian cancer

Anticancer Research

Volumn 32, Issue 1 PART 2, 2012, Pages 351-357

  Cordes, Tim ^a   Hoellen, F ^a   Dittmer, C ^a   Salehin, D ^b   Kummel S ^c   Friedrich, M ^b   Koster F ^a   Becker, S ^a   Diedrich, K ^a   Thill, M ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Helios Hospital Krefeld   (Germany)

^c Hospital Essen Mitte   (Germany)

Author keywords

15 hydroxyprostaglandin dehydrogenase; Breast cancer; Cyclooxygenase 2; Ovarian cancer; PGE 2; Prostaglandin receptor; Vitamin D receptor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCITRIOL; CYCLOOXYGENASE 2; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; VITAMIN D RECEPTOR;

ADULT; AGED; BLOOD LEVEL; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITRIOL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, CALCITRIOL; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84855991262     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable- diseases/cancer
2. Kloss M, Fischer D, Thill M, Friedrich M, Cordes T, Salehin D, Diedrich K and Köster F: Vitamin D, calcidiol and calcitriol regulate vitamin D metabolizing enzymes in cervical and ovarian cancer cells. Anticancer Res 30(11): 4429-4434, 2010.
3. Fischer D, Becker S, Cordes T, Bücker B, Diedrich K, Friedrich M, Salehin D and Thill M: Anticancer Res 29(9): 3641-3645, 2009.
4. Cordes T, Diesing D, Becker S, Fischer D, Diedrich K and Friedrich M: J Steroid Biochem Mol Biol 103(3-5): 326-329, 2007.
5. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, Salehin D and Friedrich M: Anticancer Res 29(9): 3619-3625, 2009.
6. Herschman HR: Prostaglandin synthase 2. Biochem Biophys Acta 1299(1): 125-140, 1996.
7. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO and Scambia G: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13(5): 1205-1211, 2002. (Pubitemid 34960128)
8. Fujimoto J, Toyoki H, Sakaguchi H, Jahan I, Alam SM and Tamaya T: Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer: Oncol Rep 15(1): 21-25, 2006.
9. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA and Derchain SF: Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer 17(3): 607-614, 2007. (Pubitemid 46744003)
10. Denken C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 97(12): 2978-2987, 2003. (Pubitemid 36676251)
11. Half E, Tang XN, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002. (Pubitemid 34408488)
12. Diaz-Cruz ES, Shapiro CL and Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90(5): 2563-2570, 2005. (Pubitemid 40686292)
13. Khuder SA and Mutgi AB: Breast cancer and NSAID use: a metaanalysis. Br J Cancer 84: 1188-1192, 2001. (Pubitemid 32511336)
14. Grant WB and Garland CF: Intern Med 252(2): 178-179; author reply 179-180, 2002.
15. Friedrich M: Vitamin D and breast cancer: new approaches for hormonal therapy of breast cancer. Clin Exp Obstet Gynecol. 27(2): 77-82, 2000.
16. Cui Y and Rohan TE: Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev 15(8): 1427-1437, 2006. (Pubitemid 44299311)
17. Colston KW and Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9(1): 45-59, 2002. (Pubitemid 34298363)
18. 3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 26(4A): 2615-2620, 2006.
19. Malloy PJ, Pike JW and Feldman D: The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 20(2): 156-188, 1999. (Pubitemid 29341671)
20. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM and Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65(17): 7917-7925, 2005. (Pubitemid 41297270)
21. Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E, Welsh JC, Byrne B and Narvaez CJ: Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 83: 85-92, 2002. (Pubitemid 37040644)
22. Vitamin D and breast cancer. In: Vitamin D, 2nd ed. Feldman D, Pike JW and Glorieux FH (eds.). San Diego: Elsevier Academic Press pp. 1663-1677, 2005.
23. Welsh J: Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 22(Suppl 2): V86-V90, 2007.
24. Denken C, Winzer KJ, Müller BM, Weichen W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 97(12): 2978-2987, 2003. (Pubitemid 36676251)
25. Nassar A, Radhakishnan A, Cabero IA, Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer: Correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15(3): 255-259, 2007. (Pubitemid 47329915)
26. Watanabe O, Shimizu T, Imamura, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Aiba M and Ogawa K: Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23(4): 3215-3221, 2003.
27. Yoshimura N, Sano H, Okamoto M, Akioka K, Ushogome H, Kadotani Y, Yoshimura R, Nobori S, Higuchi A, Ohmori Y and Nakamura K: Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today 33: 805-811, 2003. (Pubitemid 37357652)
28. Kelly LM, Hill ADK, Kennedy S, Connolly EM, Ramanath R, The S, Dijkstra B, Purcell R, McDermott EW and O'Higgins N: Lack of prognostic effect of COX-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29: 707-710, 2002.
29. Boland GP, Butt IP, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429, 2004. (Pubitemid 38250640)
30. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55(12): 2556-2559, 1995.
31. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66(15): 7818-7823, 2006. (Pubitemid 44289243)
32. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002. (Pubitemid 34130608)
33. Chang SH, Ai Y, Breyer RM, Lane TF and Hla T: The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 65(11): 4496-4499, 2005. (Pubitemid 40740782)
34. Subbaramaiah K, Hudis C, Chang SH, Hla T and Dannenberg AJ: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283(6): 3433-3444, 2008.
35. Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S and Cristofanilli M: Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 7(4): 299-312, 2008.
36. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3): 632-635, 2002. (Pubitemid 34126931)
37. Fulton AM, Ma X and Kundu N: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66: 9794-9797, 2006. (Pubitemid 44672027)
38. Krishnan AV, Peehl DM and Feldman D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 88: 363-371, 2003. (Pubitemid 36119910)
39. Peehl DM, Krishnan AV and Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133(7 Suppl): 2461S-2469S, 2003. (Pubitemid 36828855)
40. Krishnan AV, Peehl DM and Feldman D: The role of vitamin D in prostate cancer. Recent Results Cancer Res 164: 205-221, 2003.
41. Colston KW and Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9(1): 45-59, 2002. (Pubitemid 34298363)
42. Kemmis CM, Salvador SM, Smith KM and Welsh J: Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136(4): 887-892, 2006.
43. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11(9): 3579-3586, 2005. (Pubitemid 40627915)
44. Mohri T, Nakajima M, Takagi S, Komagata S and Yokoi T: MicroRNA regulates human vitamin D receptor. Int J Cancer 125(6): 1328-1333, 2009.
45. 2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5: 62, 2006.
46. Dore M, Cote LC, Mitchell A and Sirois J: Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem 46(1): 77-84, 1998. (Pubitemid 28030512)
47. Li W, Zhang HH, Xu RJ, Zhuo GC, Hu YQ and Li J: Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med Oncol 25(2): 172-177, 2008.
48. Khunnarong J, Tangjitqamol S, Manusirivithaya S, Suekwattana P and Leelahakorn S: Expression of cyclooxygenase-1 in epithelial ovarian cancer. A clinicopathological study. Asian Pac. J Cancer Prev 9(4): 757-762, 2008.
49. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA and Bundred NJ: Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 82: 118-122, 1997.
50. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC and Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1991-1997, 2005. (Pubitemid 41161213)
51. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA and Hulka BS: Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2: 283-291, 1999. (Pubitemid 29446591)
52. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D and Hankinson SE: Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res 69(5): 1885-1891, 2009.
53. Toriola AT, Surcel HM, Agborsangaya C, Grankvist K, Tuohimaa P, Toniolo P, Lukanova A, Pukkala E and Lehtinen M: Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur J Cancer 46(2): 364-369, 2010.
54. Srinath P, Rao PN, Knaus EE and Suresh MR: Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res 23: 3923-3928, 2003. (Pubitemid 37474344)
55. Narayanan BA, Narayanan NK, Pittman B and Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10: 7727-7737, 2004. (Pubitemid 39557538)
56. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J and Henner WD; ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112(2): 326-330, 2008.
57. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L and Heller G: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29(16): 2191-2198, 2011.
58. James SY, Mackay AG and Colston KW: Vitamin D derivatives in combination with 9-cis-retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14(5): 391-394, 1995.